ALX Oncology Holdings Inc.ALXONASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank57
3Y CAGR-7.9%
5Y CAGR+21.6%
Year-over-Year Change
Research and development spending
3Y CAGR
-7.9%/yr
vs +71.9%/yr prior
5Y CAGR
+21.6%/yr
Recent deceleration
Acceleration
-79.7pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
2.7x
Strong expansion
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $77.00M | -33.8% |
| 2024 | $116.37M | -17.9% |
| 2023 | $141.79M | +44.1% |
| 2022 | $98.40M | +63.5% |
| 2021 | $60.17M | +107.8% |
| 2020 | $28.96M | +77.6% |
| 2019 | $16.31M | +44.7% |
| 2018 | $11.27M | - |